A spokesman for the Israeli health insurance company, Clalit, confirmed yesterday that it also provides 93% protection against the emergence of symptoms when infected with the delta mutant.
The company, in cooperation with researchers from Harvard, analyzed data on 94,354 adolescents who received two doses of the vaccine between the ages of 12 and 18 years.
These data were compared with data from a similar number of unvaccinated adolescents. The results were published in the New England Journal of Medicine.
The study was conducted from June 8 to September 14. During this period, Israel was going through the fourth wave of Corona virus infections, during which the delta mutator was the most widespread.
It should be noted that the Pfizer/Biontech vaccine is used almost exclusively in Israel.